Misonix Stock Forecast, Price & News

Misonix (NASDAQ:MSON) Frequently Asked Questions

Is Misonix a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Misonix in the last twelve months. There are currently 3 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Misonix stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MSON, but not buy additional shares or sell existing shares.
View analyst ratings for Misonix or view top-rated stocks.

How has Misonix's stock been impacted by COVID-19?

Misonix's stock was trading at $10.68 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, MSON stock has increased by 148.5% and is now trading at $26.54.
View which stocks have been most impacted by COVID-19.

How were Misonix's earnings last quarter?

Misonix, Inc. (NASDAQ:MSON) posted its quarterly earnings results on Thursday, September, 2nd. The medical equipment provider reported ($0.26) EPS for the quarter, missing analysts' consensus estimates of ($0.24) by $0.02. The medical equipment provider had revenue of $19.69 million for the quarter. Misonix had a negative trailing twelve-month return on equity of 10.36% and a negative net margin of 19.55%.
View Misonix's earnings history.

What price target have analysts set for MSON?

3 equities research analysts have issued 12 month price objectives for Misonix's stock. Their forecasts range from $28.00 to $28.00. On average, they expect Misonix's stock price to reach $28.00 in the next year. This suggests a possible upside of 5.5% from the stock's current price.
View analysts' price targets for Misonix or view top-rated stocks among Wall Street analysts.

Who are Misonix's key executives?

Misonix's management team includes the following people:

• Stavros G. Vizirgianakis, Chief Executive Officer & Director
• Allan R. Staley, President
• Sharon W. Klugewicz, Chief Operating Officer
• Joseph P. Dwyer, Chief Financial Officer, Secretary & Treasurer
• Daniel Voic, VP-Engineering, Research & Development

What is Michael A. McManus Jr.'s approval rating as Misonix's CEO?

3 employees have rated Misonix CEO Michael A. McManus Jr. on Glassdoor.com. Michael A. McManus Jr. has an approval rating of 33% among Misonix's employees. This puts Michael A. McManus Jr. in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Misonix's key competitors?

Some companies that are related to Misonix include QAD (QADA), QAD (QADB), Formula Systems (1985) (FORTY), DeNA (DNACF), GREE (GREZF), Mitel Networks (MNW), Alps Alpine (APELY), Himax Technologies (HIMX), PubMatic (PUBM), indie Semiconductor (INDI), Auction Technology Group (ATG), Impinj (PI), Lilium (LILM), CSG Systems International (CSGS) and Oxford Instruments (OXINF).
View all of MSON's competitors.

What other stocks do shareholders of Misonix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Misonix investors own include Edap Tms (EDAP), (CGC), Varian Medical Systems (VAR), Sociedad Química y Minera de Chile (SQM), Avadel Pharmaceuticals (AVDL), Second Sight Medical Products (EYES), Aldeyra Therapeutics (ALDX), Ampio Pharmaceuticals (AMPE), Ardelyx (ARDX) and Athenex (ATNX).

What is Misonix's stock symbol?

Misonix trades on the NASDAQ under the ticker symbol "MSON."

Who are Misonix's major shareholders?

Misonix's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (4.64%), Tamarack Advisers LP (2.30%), Pura Vida Investments LLC (1.25%), Geode Capital Management LLC (1.18%), Acuitas Investments LLC (0.92%) and Magnetar Financial LLC (0.90%). Company insiders that own Misonix stock include Joseph P Dwyer and Stavros G Vizirgianakis.
View institutional ownership trends for Misonix.

Which institutional investors are selling Misonix stock?

MSON stock was sold by a variety of institutional investors in the last quarter, including Pura Vida Investments LLC, Acuitas Investments LLC, BlackRock Inc., California State Teachers Retirement System, Raymond James Financial Services Advisors Inc., DAVENPORT & Co LLC, New York State Common Retirement Fund, and Deutsche Bank AG.
View insider buying and selling activity for Misonix or view top insider-selling stocks.

Which institutional investors are buying Misonix stock?

MSON stock was bought by a variety of institutional investors in the last quarter, including Magnetar Financial LLC, DLD Asset Management LP, K2 Principal Fund L.P., Morgan Stanley, Beryl Capital Management LLC, Barclays PLC, Gabelli Funds LLC, and Goldman Sachs Group Inc.. Company insiders that have bought Misonix stock in the last two years include Joseph P Dwyer, and Stavros G Vizirgianakis.
View insider buying and selling activity for Misonix or or view top insider-buying stocks.

How do I buy shares of Misonix?

Shares of MSON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Misonix's stock price today?

One share of MSON stock can currently be purchased for approximately $26.54.

How much money does Misonix make?

Misonix has a market capitalization of $462.06 million and generates $74.02 million in revenue each year.

How many employees does Misonix have?

Misonix employs 254 workers across the globe.

What is Misonix's official website?

The official website for Misonix is www.misonix.com.

Where are Misonix's headquarters?

Misonix is headquartered at 1938 NEW HIGHWAY, FARMINGDALE NY, 11735.

How can I contact Misonix?

Misonix's mailing address is 1938 NEW HIGHWAY, FARMINGDALE NY, 11735. The medical equipment provider can be reached via phone at (631) 694-9555 or via fax at 631-694-9412.